(Z)-methyl 3-cyanohex-2-enoate | 1421868-96-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-methyl 3-cyanohex-2-enoate
• 英文别名: (Z)-methyl 3-cyano-2-hexenoate；methyl (Z)-3-cyanohex-2-enoate
• CAS: 1421868-96-3
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: MHOPMHISHZLQNK-ALCCZGGFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-methyl 3-cyanohex-2-enoate 在 Saccharomyces pastorianus old yellow enzyme, isoenzyme OYE₃ 、 还原型辅酶Ⅰ 作用下， 以 aq. buffer 为溶剂， 反应 24.0h， 以99%的产率得到
  参考文献：
  名称：

  Chemoenzymatic Asymmetric Synthesis of Pregabalin Precursors via Asymmetric Bioreduction of β-Cyanoacrylate Esters Using Ene-Reductases

  摘要：

  The asymmetric bioreduction of a library of beta-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.

  DOI：

  10.1021/jo302484p
• 作为产物：
  描述：

  (Z)-ethyl 3-(trifluoromethylsulfonyloxy)hex-2-enoate 在 盐酸 、 四(三苯基膦)钯 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 135.0h， 生成 (Z)-methyl 3-cyanohex-2-enoate
  参考文献：
  名称：

  Chemoenzymatic Asymmetric Synthesis of Pregabalin Precursors via Asymmetric Bioreduction of β-Cyanoacrylate Esters Using Ene-Reductases

  摘要：

  The asymmetric bioreduction of a library of beta-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.

  DOI：

  10.1021/jo302484p

文献信息

• Asymmetric Amination of α-Chiral Aliphatic Aldehydes <i>via</i> Dynamic Kinetic Resolution to Access Stereocomplementary Brivaracetam and Pregabalin Precursors
  作者：Christine S. Fuchs、Judith E. Farnberger、Georg Steinkellner、Johann H. Sattler、Mathias Pickl、Robert C. Simon、Ferdinand Zepeck、Karl Gruber、Wolfgang Kroutil

  DOI：10.1002/adsc.201701449

  日期：2018.2.15

  numerous α‐chiral, optically pure amines, serving as important building blocks for APIs. Here we elaborate on the development of transaminases recognizing the α‐chiral centre adjacent to an aldehyde moiety with aliphatic residues, opening up concepts for novel synthetic routes to the antiepileptic drugs Brivaracetam and Pregabalin. The transformation proceeded via dynamic kinetic resolution (DKR) based

  在过去的几十年中，生物催化已经成为活性药物成分（API）不对称合成的必不可少且用途广泛的工具。在这种情况下，尤其是转氨酶（TAs）已成功用于制备多种α-手性，光学纯胺，是API的重要组成部分。在这里，我们详细介绍了转氨酶的开发，该酶识别具有脂肪族残基的醛部分附近的α-手性中心，为抗癫痫药BrivaraceTAm和Pregabalin的新颖合成路线开辟了概念。转型通过动态动力学拆分（DKR）基于醛对映异构体的生物诱导外消旋作用，可实现外消旋底物的定量转化胺化。介质，底物和酶工程技术都可以以高光学纯度获得立体互补药物胺前体的（R）和（S）对映体。